Literature DB >> 35587209

The Impact of Pharmacotherapy of Childhood-Onset Psychiatric Disorders on the Development of Substance Use Disorders.

Timothy E Wilens1, Diana W Woodward1, Je Deuk Ko1, Amy F Berger1, Colin Burke1, Amy M Yule2.   

Abstract

Background and Objective: Child- and adolescent-onset psychopathology is known to increase the risk for developing substance use and substance use disorders (SUDs). While pharmacotherapy is effective in treating pediatric psychiatric disorders, the impact of medication on the ultimate risk to develop SUDs in these youth remains unclear.
Methods: We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) systematic review of peer-reviewed literature published on PubMed through November 2021, examining pharmacological treatments of psychiatric disorders in adolescents and young adults and their effect on substance use, misuse, and use disorder development.
Results: Our search terms yielded 21 studies examining the impact of pharmacotherapy and later SUD in attention-deficit/hyperactivity disorder (ADHD), two studies on Major Depressive Disorder, and three studies on psychotic disorders. The majority of these studies reported reductions in SUD (N = 14 sides) followed by no effects (N = 10) and enhanced rates of SUD (N = 2). Studies in ADHD also reported that earlier-onset and longer-duration treatment was associated with the largest risk reduction for later SUD. Conclusions: Overall, pharmacological treatments for psychiatric disorders appear to mitigate the development of SUD, especially when treatment is initiated early and for longer durations. More studies on the development of SUD linked to the effects of psychotherapy alone and in combination with medication, medication initiation and duration, adequacy of treatment, non-ADHD disorders, and psychiatric comorbidity are necessary.

Entities:  

Keywords:  adolescent; pharmacotherapy; psychiatric disorders; substance use

Mesh:

Year:  2022        PMID: 35587209      PMCID: PMC9145257          DOI: 10.1089/cap.2022.0016

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   3.031


  59 in total

1.  Does the medicating ADHD increase or decrease the risk for later substance abuse?

Authors:  Timothy E Wilens
Journal:  Braz J Psychiatry       Date:  2003-09       Impact factor: 2.697

2.  Untreated depression and non-medical use of prescription pain relievers: findings from the National Survey on Drug Use and Health 2008-2014.

Authors:  Giuseppe Carrà; Francesco Bartoli; Marc Galanter; Cristina Crocamo
Journal:  Postgrad Med       Date:  2018-11-27       Impact factor: 3.840

3.  Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

Authors:  J Biederman; T Wilens; E Mick; T Spencer; S V Faraone
Journal:  Pediatrics       Date:  1999-08       Impact factor: 7.124

4.  Differences in Psychiatric Problems and Criminality Between Individuals Treated With Central Stimulants Before and After Adulthood.

Authors:  Kirsten Rasmussen; Tom Palmstierna; Sten Levander
Journal:  J Atten Disord       Date:  2015-03-20       Impact factor: 3.256

5.  Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study.

Authors:  Slavica K Katusic; William J Barbaresi; Robert C Colligan; Amy L Weaver; Cynthia L Leibson; Steven J Jacobsen
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-10       Impact factor: 2.576

6.  Increased risk for suicidal behavior in comorbid bipolar disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

Authors:  Maria A Oquendo; Dianne Currier; Shang-Min Liu; Deborah S Hasin; Bridget F Grant; Carlos Blanco
Journal:  J Clin Psychiatry       Date:  2010-07       Impact factor: 4.384

7.  Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder.

Authors:  Timothy E Wilens; Joseph Biederman; MaryKate Martelon; Courtney Zulauf; Jesse P Anderson; Nicholas W Carrellas; Amy Yule; Janet Wozniak; Ronna Fried; Stephen V Faraone
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

8.  A Prospective Examination of the Association of Stimulant Medication History and Drug Use Outcomes among Community Samples of ADHD Youths.

Authors:  Ken C Winters; Susanne Lee; Andria Botzet; Tamara Fahnhorst; George M Realmuto; Gerald J August
Journal:  J Child Adolesc Subst Abuse       Date:  2011-09-09

9.  Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.

Authors:  Joseph Biederman
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

10.  A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.

Authors:  Stephen V Faraone; Joseph Biederman; Timothy E Wilens; Joel Adamson
Journal:  Psychol Med       Date:  2007-03-12       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.